Breaking News
FONT-SIZE Plus   Neg
Share SHARE

Aurobindo Pharma Gets Final Approvals For Quetiapine Fumarate Tablets

Manufacturer of generic pharmaceuticals and active pharmaceutical ingredients Aurobindo Pharma Ltd. announced that the company had obtained final approvals from the US Food & Drug Administration or US FDA to market Quetiapine Fumarate tablets 25mg, 50mg, 100mg, 150mg, 200mg, 300mg and 400mg.

Quetiapine Fumarate tablets 25mg, 50mg, 100mg, 150mg, 200mg, 300mg and 400mgare the generic equivalent of AstraZeneca LP's Seroquel tablets 25mg, 50mg, 100mg, 150mg, 200mg, 300mg and 400mg. These tablets are indicated for the treatment of serious psychotic disorders such as Schizophrenia and Bipolar Disorder and fall under the Neurological (CNS) therapeutic category.

The company said the product had been approved out of Unit III facility in Hyderabad, India.

Aurobindo now has a total of 147 ANDA approvals (118 final approvals and 29 tentative approvals)from US FDA.

AT the BSE, Aurobindo Pharma shares are currently trading at Rs.116.55, up 1.66 percent from the previous close.

Click here to receive FREE breaking news email alerts for Aurobindo Pharma Ltd. and others in your portfolio

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Editors Pick
New Zealand's diary giant Fonterra lowered its forecast for farmer payouts for the 2014/15 season citing falling world dairy prices and a strong New Zealand dollar. The 2014/15 Farmgate Milk Price forecast was lowered to NZ$6 per kg of milk solids from its earlier estimate of NZ$7 per kg in May, the... Home improvement and building products company Masco Corp. said Monday after the markets closed that its second quarter profit jumped 78% from last year, as revenue increased and margins improved amid strong performance of its Plumbing Products, Installation and Other Services and Decorative Architectural Products segments. American Financial Group Inc. (AFG) Monday reported second-quarter net earnings of $106 million or $1.15 per share, compared to $110 million or $1.20 per share last year. Core net operating earnings were $99 million or $1.07 per share, compared to $87 million or $0.96 per share last year. Total...
comments powered by Disqus
FREE Newsletters, Analysis & Alerts

 

Stay informed with our FREE daily Newsletters and real-time breaking News Alerts. Sign up to receive the latest information on business news, health, technology, biotech, market analysis, currency trading and more.